Skip navigation
AI Applications Summit header

Healthcare &9642; Pharma &9642; Biotech

Download Brochure
Register Now

December 11-12, 2017
Cambridge, MA

December 11-12, 2017 Royal Sonesta Boston Cambridge, MA

Data Privacy Summit for Life Sciences banner ad
Risk-Based Trial Management and Monitoring banner ad

Agenda | AI Application Summit

Agenda Download as PDF

DAY ONE | Monday, December 11, 2017


Registration and Breakfast in the Innovation Zone


Chair's Opening Remarks —

Thriving in the New Data-Driven Healthcare Market

  • What are the goals of this data-driven revolution and how far are we from starting to achieve them?
  • Will a completely new business paradigm emerge for next-generation health systems to optimize operations and patient care?
  • Is there room for disruptive entrepreneurs alongside existing companies to succeed in data-driven drug discovery and development?
  • Roll up your sleeves and get ready to discuss what is working and what is getting in the way of flourishing in the world of MoneyBall Medicine

Harry Glorikian
General Partner, New Ventures Funds;
Author, MoneyBall Medicine: Thriving in the New Data-Driven Healthcare Market


AI Investment and Application Landscape — Setting the Stage

Pharma/Biotech AI Application Landscape

  • Defining the spectrum of technologies and platforms comprising AI in the life sciences
  • The key drivers driving life science AI adoption
  • Examining the maturity of AI technologies and their paths forward

Alan S. Louie, Ph.D.
Research Director, Life Sciences, IDC Health Insights

Hospital/Health System AI Application Landscape

  • Innovations and possibilities of diagnostic AI tools
  • AI for healthcare/hospital operational efficiency
  • The challenges and hurdles of adopting AI in healthcare

Daniel Faggella
Founder & CEO, TechEmergence

AI Investment Landscape


Artificial Intelligence in Healthcare — From Drug Discovery to Digital Health

  • Using AI to discover novel therapeutic targets and build a pharma pipeline
  • AI guided clinical development and patient stratification
  • Data driven AI approaches in predictive analytics and population management

Slava Akmaev, Ph.D.
Senior VP and Chief Analytics Officer, BERG


Innovation Zone Break and One-to-One Meetings with Analysts


Provider & Biopharma Data Collaboration to Move the Needle

  • Data is the raw material that drives scientific discovery and data quality has a significant effect on the conclusions that one can draw - how do you ensure and measure data quality from disparate sources?
  • Data interpretation requires complete and accurate metadata - what are the implications of this for biopharma and providers?
  • Reproducible research demands release of both data and open source software - is this possible to achieve?

John D. Halamka, MD
CIO, Beth Israel Deaconess Medical Center;
Professor of Emergency Medicine, Harvard Medical School

John Quackenbush, Ph.D.
Professor of Biostatistics and Computational Biology
Dana-Farber Cancer Institute and Harvard TH Chan School of Public Health

Sandy Farmer, Ph.D.
Executive Director, WRD Genome Sciences & Technologies, Pfizer Inc

  • Before you can apply the power of data science, you must have a strategy for defining what is data
  • Many biotechnology companies don’t start with defining their informatics environments as their initial focus is on the science itself, not the storage and usability
  • We are developing a corporate wide data strategy which connects 1) real world evidence and data 2) genetic variation in the patient population to 3) molecular interactions with the protein target

Georgia McGaughey, Ph.D.
Senior Director, Global Modeling & Informatics Group, Vertex Pharmaceuticals


Successfully Navigating AI Vendor Management and Partnerships

  • Given the current immaturity of AI solutions in healthcare – where does one start with vendor management and partnership?
  • Will there be a "one size fits all" for a platform play? Or do we need to evaluate best of breed solutions?
  • How will rampant M&A activity in the AI market impact vendor management and partnerships?
  • What security implications are there for AI in highly regulated industries such as healthcare and life science?

Lynne Dunbrack
Research Vice President, IDC Health Insights

Mark H. Michalski, MD
Executive Director, MGH & BWH Center for Clinical Data Science


Lunch in the Innovation Zone and One-to-One Meetings with Analysts


The Human Side of AI – Getting from Technological Euphoria to Clinical Impact

  • Hear from industry and clinical thought leaders about the realities and near term impact of AI, machine, and deep learning
  • Real-world case studies from early adopters of AI technologies will cover how these technologies areimpacting care delivery and drug discovery
  • Discuss the challenges to clinicians, regulators, and patients as these new technologies take root in healthcare
  • Learn how to prepare your organization for the cultural shifts that AI will force

Michael S. Blum, MD FACC
Associate Vice Chancellor for Informatics, Chief Digital Technology Officer, Director, Center for Digital Health Innovation;
Professor of Medicine, Cardiology, University of California, San Francisco

Sameer Badlani, MD, FACP
VP & Chief Health Information Officer, Sutter Health


Novel Business Models With AI Augmented Human Intelligence

  • How AI augments human intelligence in the biomedical space, and how this can dramatically improve productivity across the entire healthcare spectrum (from drug discovery/development to commercialization of drugs). This enables a broad range of potential business models, from traditional software licensing to unconventional joint ventures/partnerships between AI players and a wider range of players.
  • Regardless of the business model to be pursued and the specific area of focus (whether it's drug discovery or commercialization...), the key to success is merging state-of-the-art AI capabilities with exceptional domain expertise.
  • Qrativ as an example of a novel type of joint venture that is powered by AI where an AI player (nference) partners with a hospital system (Mayo) to create a new model to discover and develop treatments for diseases with unmet need.

Murali Aravamudan
Founder and CEO
nference and Qrativ (Mayo Clinic - nference Joint Venture)


Innovation Zone Break and One-to-One Meetings with Analysts


Data Access & Usability

  • Overcoming interoperability issues — what can you accomplish with the current generation of health IT tools?
  • Proprietary standards, data siloes, privacy concerns — getting over these hurdles to improve data transparency, analysis and usability
  • Data Storage — what works and what you need to really understand about the pros and cons of available options

Jennifer K. Pai, ScD, MHS
Director, Data Sciences & Strategic Partnerships,
Center for Observational & Real-world Evidence (CORE), Merck & Co., Inc.


Balancing Security, Privacy and Compliance with AI enabled Accessibility and Usability of Data

  • What are the legal and ethical issues to consider around allowing AI and related technologies into decision making in the healthcare field?
  • Data mining rules: Who has the right to analyze what type of data and what rules need to be in place regarding anonymizing the collected data
  • What are the most critical issues to consider when creating governing policies around access rights to data?
  • What level of privacy and security protection must be maintained when data is transferred to a third party?
  • Beyond who owns the data – who has the right to know what the data has revealed through the use of AI technologies?

Jennifer S. Geetter, Esq.
Partner, McDermott Will & Emery LLP

Eric Perakslis, Ph.D.
Senior Vice President, Informatics Strategy and Professional Affairs, Takeda Pharmaceuticals


Big Data — Story — Insights — Therapeutic Hypothesis: Closing the Gap to Transform Data into Actual Therapies

William Chen, Ph.D.
Director, Systems Biology, Biogen

Making Data Usable — Connecting the Care Community to Improve Patient Outcomes

  • Describe how Information Delivery Services uses data connectivity and exchange.
  • Demonstrate how information integration into workflow can improve care coordination.
  • Intuitive distribution of results through the use of metadata within the clinical data segment stream.
  • Recognize how the real-time delivery of results and notifications to clinicians and care managers provides real-time insight.

Joseph Fisne, MS, CPHIMS
VP & Associate Chief Information Officer, IT Applications, Geisinger Health System


Industry Perspective & Discussion Security and Compliance Pharma & Biotech

Lessons Learned From Boston Children’s —
When Hacktivists Target Your Hospital

  • Convey risks all healthcare and life sciences entities now have with reliance on digital technology, including AI, in the age of cyberattacks
  • Enumerate specific risk areas and approaches to mitigation, especially considering risk to routine operations, and not just to data loss
  • Understand critical importance of investment in cybersecurity technology and personnel, and of organizational focus on it

Daniel Nigrin, MD, MS
Senior VP & Chief Information Officer,
Boston Children's Hospital;
Asst. Professor of Pediatrics, Harvard Medical School


Innovation Zone Presentations Using Machine Learning to Predict Drug Binding Targets and Side-Effects

How much can you learn in five minutes? Quite a bit. Immediately prior to the Innovation Zone Reception, hear these companies deliver quick-hitting presentations on the latest products, new releases, exciting changes, and more. Each presenter will speak for 5 minutes and then will be available to answer questions during the Innovation Zone reception.

  • Machine learning has the potential to dramatically accelerate early-stage drug development by focusing costly and tedious experimentation
  • OneThree has developed a platform of 3 machine-learning algorithms to predict: 1) gene essentiality, 2) binding targets of small molecules in development, and 3) clinical level side effects (such as heart attacks or neutropenia)
  • Platform has benchmarked up to a 90% accuracy and has led to novel discovery on compounds in Phase II development

Neel S. Madhukar, Ph.D.
CEO, OneThree Biotech


Close of Day One — Innovation Zone Reception


DAY TWO | Tuesday, December 12, 2017


Breakfast in the Innovation Zone and One-to-One Meetings with Analysts


Chair Remarks – Pharma/Biotech

Chair Remarks – Hospital/Health System


How Pharma R&D Makes These Key Business Themes Smarter by Leveraging AI Underneath These Applications:

  • Lab of the Future
  • Precision Medicine
  • Digital Health

Anthony Rowe, Ph.D.
Director, Business Technology Leader – Immunology TA, JPC, JHML, ImmunoScience COE
Janssen Research and Development IT

Unlock Hidden Insights Trapped in "Dark Data" Using Natural Language Processing

  • The impact of not knowing what is in the dark data and why you should care
  • Getting better outcomes by using all of your data
  • The key to making unstructured text relevant for improved coding, reporting and billing
  • Implementing augmented intelligence to ensure physicians are operating at the top of their license

Craig Rhinehart
Director, Watson Health Innovation and
Market Development Strategy, IBM (Retired)


Getting to Validation — Use Cases From the Front Line — Precision Medicine

Guru Banavar
Chief Technology Officer, Viome

Disruption in the Clinical Workflow — Not a Good Thing!

  • Evolution of the clinical workflow & current state
  • Why is automation of the clinical workflow the answer?
  • The challenge of physician engagement
  • Move to where the puck will be — Automating workflow using AI and ML

Sameer Badlani, MD, FACP
VP & Chief Health Information Officer, Sutter Health


Machine Learning Uses to Propel Drug Discovery & Development

Blockchain and Artificial Intelligence in Healthcare

  • AI in drug design and discovery
  • AI for biomarker development
  • Blockchain based and AI driven platform for healthcare data management, data monetization and analysis

Polina Mamoshina
Research Scientist, Pharma AI, a division of Insilico Medicine, Inc.;
Department of Computer Science, University of Oxford


Innovation Zone Break and One-to-One Meetings with Analysts


The Power of Applications With Embedded Machine Learning for Predictive Analytics

  • Explore machine learning's role in advances in diagnoses and treatment
  • Learn how to mitigate challenges of introducing machine learning to physicians and executives
  • Examine how to prioritize machine learning applications

Cynthia Burghard
Research Director, Value-based IT Transformation Strategies, IDC Health Insights

Iya Khalil
Co-Founder & Chief Commercial Officer, GNS Healthcare


Real-World Evidence (RWE) — Improving Patient Outcomes is the Goal

  • What is Real-World Evidence and why do we need it?
  • Differences between real-world data & real-world evidence and why this is important
  • Case studies of early adopters of RWE demonstrating value to organizations
  • What does the future hold for RWD, RWE and advancements in technology?

Julie Locklear, PharmD, MBA
Vice President & Head, US Health Economics & Outcomes Research,
EMD Serono, Inc., a business of Merck KGaA, Darmstadt, Germany

S. Alandra Weaver, MPH
Director, Quality of Care and Clinical Research Programs, Crohn's & Colitis Foundation


Open Q&A and Discussion — You Take Over the Agenda for this 30-Minute Highly Engaging Session

Join AI Applications Summit speakers, IDC Analysts, and your peers in this final session dedicated to addressing your most important open issues and take this opportunity to challenge some of what you’ve heard to continue the discussion and debate. This session takes form in real-time featuring instant break-outs and small group discussions as well as general audience sharing. The “unconference” format is an opportunity to engage with speakers and ensures that everyone at the AI Applications Summit leaves with actionable insight and a more advanced AI strategy.


Close of Conference


Speaker Invites & Submissions
Event Partner Opportunities

Debra Chipman
Corey Lane Partners
[email protected]